GDC-0623
GDC-0623 is an inhibitor of MEK that prevents MEK-dependent B-Raf and KRAS signaling. GDC-0623 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for several cancers.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18926322
| Cas No. |
1168091-68-6 |
|---|---|
| Purity |
≥98% |
| Formula |
C16H14FIN4O3 |
| Formula Wt. |
456.21 |
| IUPAC Name |
5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide |
| Appearance |
Beige Powder |
Hatzivassiliou G, Haling JR, Chen H, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 2013 Sep 12;501(7466):232-6. PMID: 23934108.
